cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.27210757.v1
title: Prognostic value of [<sup>18</sup>F]FDG PET/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study

description: This retrospective study aimed to evaluate the prognostic value of [<sup>18</sup>F]FDG parameters in patients with visceral and bone metastatic hormone-sensitive prostate cancer (mHSPC). This analysis included the mHSPC patients who underwent [<sup>18</sup>F]FDG PET/CT at the initial diagnosis. Baseline characteristics were analyzed, and the uptake of [<sup>18</sup>F]FDG was quantified using SUV<sub>max</sub>. Kaplan–Meier and Cox proportional hazard regression analysis were employed to evaluate the correlation between SUV<sub>max</sub> and patient survival. Among the 267 patients enrolled, 90 (33.7%) presented with visceral metastases and 177 (66.3%) had bone metastases. The median follow-up for the visceral metastasis group was 35.5 months (IQR 26–53.8 months). The median overall survival for patients with lung, liver, or both metastases were 30, 21 and 17 months, respectively. Patients exhibiting higher [<sup>18</sup>F]FDG uptake in metastatic lesions experienced shorter overall survival (OS) in comparison to those with lower [<sup>18</sup>F]FDG uptake, both in the visceral metastases group (17 vs. 31 months, <i>p</i> = 0.002) and the bone metastases group (27.5 vs. 34.5 months, <i>p</i> &lt; 0.001). Cox regression analysis further revealed that increased [<sup>18</sup>F]FDG uptake in metastatic lesions emerged as a significant risk factor in both OS and progression-free survival (PFS). In contrast, the variability in [<sup>18</sup>F]FDG uptake in primary lesions did not provide a reliable indicator for predicting prognosis. In mHSPC patients, higher [<sup>18</sup>F]FDG uptake in metastatic lesions indicates shorter survival and increased risk of disease progression. The [<sup>18</sup>F]FDG SUV<sub>max</sub> in primary tumors did not show significant prognostic value. Our study underscores the unique prognostic potential of [<sup>18</sup>F]FDG PET/CT in mHSPC patients, highlighting its importance in the management of both bone and visceral metastases.
DOI: 10.6084/m9.figshare.27951786
title: Multi-omics profiling highlights karyopherin subunit alpha 2 as a promising biomarker for prognosis and immunotherapy respond in pediatric and adult adrenocortical carcinoma

description: Adrenocortical carcinoma (ACC) afflicts both pediatric and adult populations and is characterized by dismal prognosis and elevated mortality. Given the inconsistent therapeutic benefits and significant side effects associated with the conventional chemotherapy agent, mitotane, and the nascent stage of immunotherapy and targeted treatments, there is an urgent need to identify novel prognostic biomarkers and therapeutic targets in ACC. Utilizing multi-omic datasets from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), we employed Weighted Gene Co-expression Network Analysis (WGCNA), Cox regression, Receiver Operating Characteristic (ROC) curves, and survival analyses to sift for potential prognostic biomarkers. We subsequently validated these findings through immunohistochemistry and cell assays, and delved into the biological role of KPNA2 in ACC through functional enrichment analysis, mutational landscape, and immune cell infiltration. A total of 77 progression-associated genes with aberrant chromosomal accessibility were discerned within the TCGA-ACC dataset. By integrating ROC and Cox regression from GEO datasets, KPNA2 emerged as an independent risk factor portending poor outcomes in ACC. ATAC-seq analysis revealed attenuated chromatin accessibility of KPNA2 in cases with unfavorable prognosis. Immunohistochemistry corroborated elevated KPNA2 expression, which was linked to enhanced proliferation and invasion. Elevated KPNA2 levels were found to activate oncogenic pathways while simultaneously suppressing immunological responses. Immune infiltration analysis further revealed a decrement in CD8+ T-cell infiltration in KPNA2-high cohorts. This study demonstrates the clinical and biological significance of KPNA2 in ACC and suggests that KPNA2 could serve as a promising biomarker for predicting prognosis and immunotherapeutic responses in pediatric and adult ACC patients.
DOI: 10.6084/m9.figshare.27951786.v1
title: Multi-omics profiling highlights karyopherin subunit alpha 2 as a promising biomarker for prognosis and immunotherapy respond in pediatric and adult adrenocortical carcinoma

description: Adrenocortical carcinoma (ACC) afflicts both pediatric and adult populations and is characterized by dismal prognosis and elevated mortality. Given the inconsistent therapeutic benefits and significant side effects associated with the conventional chemotherapy agent, mitotane, and the nascent stage of immunotherapy and targeted treatments, there is an urgent need to identify novel prognostic biomarkers and therapeutic targets in ACC. Utilizing multi-omic datasets from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), we employed Weighted Gene Co-expression Network Analysis (WGCNA), Cox regression, Receiver Operating Characteristic (ROC) curves, and survival analyses to sift for potential prognostic biomarkers. We subsequently validated these findings through immunohistochemistry and cell assays, and delved into the biological role of KPNA2 in ACC through functional enrichment analysis, mutational landscape, and immune cell infiltration. A total of 77 progression-associated genes with aberrant chromosomal accessibility were discerned within the TCGA-ACC dataset. By integrating ROC and Cox regression from GEO datasets, KPNA2 emerged as an independent risk factor portending poor outcomes in ACC. ATAC-seq analysis revealed attenuated chromatin accessibility of KPNA2 in cases with unfavorable prognosis. Immunohistochemistry corroborated elevated KPNA2 expression, which was linked to enhanced proliferation and invasion. Elevated KPNA2 levels were found to activate oncogenic pathways while simultaneously suppressing immunological responses. Immune infiltration analysis further revealed a decrement in CD8+ T-cell infiltration in KPNA2-high cohorts. This study demonstrates the clinical and biological significance of KPNA2 in ACC and suggests that KPNA2 could serve as a promising biomarker for predicting prognosis and immunotherapeutic responses in pediatric and adult ACC patients.
DOI: 10.6084/m9.figshare.27951789
title: Astilbin exerts anti-hypersensitivity by regulating metabolic demand and neuronal activity in rodent model of neuropathic pain

description: <i>Astilbe chinensis</i>, is a traditional Chinese medicine commonly employed for pain management. However, its primary active ingredient remains a subject of debate. Spinal nerve ligation (SNL) and formalin-induced pain models were employed. Network pharmacology and bioinformatics were utilized to identify targets. Verification was performed through spinal cord double immunofluorescence staining, quantitative PCR and whole-cell recording techniques. In experiments conducted on neuropathic rats, both systemic and intrathecal administration of astilbin, an essential constituent, exhibited a noteworthy and dose-dependently decrease in chronic and acute pain behaviours. The ED<sub>50</sub> value, which represents the dose at which 50% effectiveness is achieved, was measure at 7.59 μg, while the <i>E</i><sub>max</sub> value, indicating the maximum attainable effect, was found to be 60% of the maximal possible effect (% MPE). Forty-two shared targets were identified, enriching the metabolic and synaptic pathways in the network pharmacology analysis, as confirmed by transcriptomic analysis. Weighted gene co-expression network analysis (WGCNA) revealed a strong correlation between the anti-nociceptive effects of astilbin and neuronal metabolic processes. Spinal functional ultrasound (FUS) analysis indicated increased spinal blood flow intensity and changes in metabolism-related enzyme activity, including stearoyl-CoA desaturase (<i>Scd</i>), 17beta-hydroxysteroid dehydrogenase (<i>Hsd17b7</i>) and sterol 14alpha-demethylase (<i>Cyp51</i>) in neuropathic rats, pretreatment with astilbin decreased formalin-induced blood flow in acute pain. Bath application of astilbin dose-dependently inhibited neuronal activity by reducing the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs) without affecting miniature inhibitory postsynaptic currents (mIPSCs). In summary, this study provides evidence that astilbin alleviates pain by modulating neuronal metabolic processes and synaptic homeostasis.
DOI: 10.6084/m9.figshare.27951789.v1
title: Astilbin exerts anti-hypersensitivity by regulating metabolic demand and neuronal activity in rodent model of neuropathic pain

description: <i>Astilbe chinensis</i>, is a traditional Chinese medicine commonly employed for pain management. However, its primary active ingredient remains a subject of debate. Spinal nerve ligation (SNL) and formalin-induced pain models were employed. Network pharmacology and bioinformatics were utilized to identify targets. Verification was performed through spinal cord double immunofluorescence staining, quantitative PCR and whole-cell recording techniques. In experiments conducted on neuropathic rats, both systemic and intrathecal administration of astilbin, an essential constituent, exhibited a noteworthy and dose-dependently decrease in chronic and acute pain behaviours. The ED<sub>50</sub> value, which represents the dose at which 50% effectiveness is achieved, was measure at 7.59 μg, while the <i>E</i><sub>max</sub> value, indicating the maximum attainable effect, was found to be 60% of the maximal possible effect (% MPE). Forty-two shared targets were identified, enriching the metabolic and synaptic pathways in the network pharmacology analysis, as confirmed by transcriptomic analysis. Weighted gene co-expression network analysis (WGCNA) revealed a strong correlation between the anti-nociceptive effects of astilbin and neuronal metabolic processes. Spinal functional ultrasound (FUS) analysis indicated increased spinal blood flow intensity and changes in metabolism-related enzyme activity, including stearoyl-CoA desaturase (<i>Scd</i>), 17beta-hydroxysteroid dehydrogenase (<i>Hsd17b7</i>) and sterol 14alpha-demethylase (<i>Cyp51</i>) in neuropathic rats, pretreatment with astilbin decreased formalin-induced blood flow in acute pain. Bath application of astilbin dose-dependently inhibited neuronal activity by reducing the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs) without affecting miniature inhibitory postsynaptic currents (mIPSCs). In summary, this study provides evidence that astilbin alleviates pain by modulating neuronal metabolic processes and synaptic homeostasis.
DOI: 10.6084/m9.figshare.27930866
title: Development and validation of the prediction model based on autophagy-associated genes in bronchopulmonary dysplasia

description: Bronchopulmonary dysplasia (BPD) is the most common chronic respiratory disease among preterm infants. Owing to the limitations in current diagnostic methods, developing a predictive model for BPD is crucial. Using 243 autophagy-associated genes and dataset GSE32472, differential expression of autophagy-associated genes was identified at postnatal days 5, 14, and 28 between BPD patients and controls. LASSO and multivariate logistic regression analyses were performed to screen for diagnostic prediction genes. Receiver Operating Characteristic, Harrell’s concordance index, and decision curve analysis (DCA) were used to evaluate the diagnostic prediction model in GSE32472 and GSE220135. A BPD mouse model was constructed and qRT-PCR and Western blot were used to verify gene expression in lung tissue. Based on <i>p</i> &lt; 0.05, we constructed a diagnostic prediction model for BPD using WIPI1, TOMM70A, BAG3, and PRKCQ. For the training database, the model’s C-index and Area under Curve were both 0.941, and a high applicability value was demonstrated by the DCA curve. These outcomes were also confirmed in the validation cohort GSE220135, demonstrating the superior diagnostic prediction capability of our approach. In addition, significant variations in immune cell infiltration were observed between BPD patients and controls. According to the results of qRT-PCR, BPD model mice had significantly lower expression levels of WIPI1, TOMM70A, BAG3, and PRKCQ than controls. We constructed and validated a diagnostic prediction model for BPD based on WIPI1, TOMM70A, BAG3, and PRKCQ. These four genes may influence BPD development by regulating immune responses and immune cells.
DOI: 10.6084/m9.figshare.27930866.v1
title: Development and validation of the prediction model based on autophagy-associated genes in bronchopulmonary dysplasia

description: Bronchopulmonary dysplasia (BPD) is the most common chronic respiratory disease among preterm infants. Owing to the limitations in current diagnostic methods, developing a predictive model for BPD is crucial. Using 243 autophagy-associated genes and dataset GSE32472, differential expression of autophagy-associated genes was identified at postnatal days 5, 14, and 28 between BPD patients and controls. LASSO and multivariate logistic regression analyses were performed to screen for diagnostic prediction genes. Receiver Operating Characteristic, Harrell’s concordance index, and decision curve analysis (DCA) were used to evaluate the diagnostic prediction model in GSE32472 and GSE220135. A BPD mouse model was constructed and qRT-PCR and Western blot were used to verify gene expression in lung tissue. Based on <i>p</i> &lt; 0.05, we constructed a diagnostic prediction model for BPD using WIPI1, TOMM70A, BAG3, and PRKCQ. For the training database, the model’s C-index and Area under Curve were both 0.941, and a high applicability value was demonstrated by the DCA curve. These outcomes were also confirmed in the validation cohort GSE220135, demonstrating the superior diagnostic prediction capability of our approach. In addition, significant variations in immune cell infiltration were observed between BPD patients and controls. According to the results of qRT-PCR, BPD model mice had significantly lower expression levels of WIPI1, TOMM70A, BAG3, and PRKCQ than controls. We constructed and validated a diagnostic prediction model for BPD based on WIPI1, TOMM70A, BAG3, and PRKCQ. These four genes may influence BPD development by regulating immune responses and immune cells.
DOI: 10.6084/m9.figshare.27309118
title: Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study

description: Transformed lymphoma occurs when indolent lymphoma transforms into more aggressive lymphoma usually associated with poor prognosis. In this study, we analysed the immunophenotypes, prognostic factors and outcomes of 35 patients with transformed lymphoma from among 306 marginal zone lymphoma (MZL), 544 follicular lymphoma (FL) and 871 chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) cases. In addition, we performed whole-exome sequencing study of seven transformed MZL (tMZL) cases. Our results demonstrate that the median time from indolent lymphoma diagnosis to transformed DLBCL was 35 months (range, 14–53 months). The 5-year overall survival (OS) and progression-free survival (PFS) rates after histological transformation (HT) were 50% and 26%, respectively. Kaplan–Meier survival analysis revealed that asynchronous HT and transformed CLL/SLL (tCLL/SLL) were significant adverse prognostic factors for OS after DLBCL HT. We identified mutations involvement in chromatin remodelling (<i>CREBBP</i> and <i>EP300</i>) and regulators of NF-κB signalling (<i>TNFAIP3, BCL10, MYD88, CD79B</i> and <i>CARD11</i>) were affected in tMZL. Whole-exome sequencing and copy-number analysis revealed that tMZL derives from the divergent evolution of an ancestral common progenitor clone (CPC). Collectively, this study provides clinicopathological characteristics of three common types of transformed lymphomas and the genetic profile of tMZL with diagnostic and therapeutic implications.
DOI: 10.6084/m9.figshare.27309118.v1
title: Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study

description: Transformed lymphoma occurs when indolent lymphoma transforms into more aggressive lymphoma usually associated with poor prognosis. In this study, we analysed the immunophenotypes, prognostic factors and outcomes of 35 patients with transformed lymphoma from among 306 marginal zone lymphoma (MZL), 544 follicular lymphoma (FL) and 871 chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) cases. In addition, we performed whole-exome sequencing study of seven transformed MZL (tMZL) cases. Our results demonstrate that the median time from indolent lymphoma diagnosis to transformed DLBCL was 35 months (range, 14–53 months). The 5-year overall survival (OS) and progression-free survival (PFS) rates after histological transformation (HT) were 50% and 26%, respectively. Kaplan–Meier survival analysis revealed that asynchronous HT and transformed CLL/SLL (tCLL/SLL) were significant adverse prognostic factors for OS after DLBCL HT. We identified mutations involvement in chromatin remodelling (<i>CREBBP</i> and <i>EP300</i>) and regulators of NF-κB signalling (<i>TNFAIP3, BCL10, MYD88, CD79B</i> and <i>CARD11</i>) were affected in tMZL. Whole-exome sequencing and copy-number analysis revealed that tMZL derives from the divergent evolution of an ancestral common progenitor clone (CPC). Collectively, this study provides clinicopathological characteristics of three common types of transformed lymphomas and the genetic profile of tMZL with diagnostic and therapeutic implications.
DOI: 10.6084/m9.figshare.26830473
title: Incidence and risk factors of VTE in lung cancer: a meta-analysis

description: Lung cancer has maintained a high prevalence and mortality. Besides, venous thromboembolism (VTE) is the third most common disease of cardiovascular disease. Lung cancer with VTE usually influenced the overall survival in the follow-up. In the development of lung cancer, vigilance against and early diagnosis of VTE is of significance. We searched the databases of PubMed, Web of Science, Embase and Cochrane for related research up to 30 November 2023 and extracted information of incidence, odds ratio (OR), hazard ratio (HR) and their 95% confidence intervals (CIs), for evaluating the incidence of VTE and its risk factors. A total of 54 articles and 873,292 records were included in our study. The pooled incidences of VTE and PE were 6% and 3%, respectively. Subgroup analysis revealed that the tumour, node and metastasis (TNM) stage (HR= 5.43, 95% CI: 2.42, 12.22), metastasis (HR= 2.67, 95% CI: 1.35, 5.29) and chemotherapy (HR= 2.27, 95% CI: 1.11, 4.65) had major influence on VTE occurrence. Lung cancer complicated with VTE is unignorable, and its occurrence varies widely by tumour staging, tissue type and treatment. The results may aid in clinical decision-making about lung cancer in higher risk with VTE and weather receiving anticoagulant prophylaxis. The pooled incidences of VTE and PE were 6% and 3% in lung cancer. LUAD, NSCLC and tumour stage III-IV have significant relevant with VTE in lung cancer.
DOI: 10.6084/m9.figshare.26830473.v1
title: Incidence and risk factors of VTE in lung cancer: a meta-analysis

description: Lung cancer has maintained a high prevalence and mortality. Besides, venous thromboembolism (VTE) is the third most common disease of cardiovascular disease. Lung cancer with VTE usually influenced the overall survival in the follow-up. In the development of lung cancer, vigilance against and early diagnosis of VTE is of significance. We searched the databases of PubMed, Web of Science, Embase and Cochrane for related research up to 30 November 2023 and extracted information of incidence, odds ratio (OR), hazard ratio (HR) and their 95% confidence intervals (CIs), for evaluating the incidence of VTE and its risk factors. A total of 54 articles and 873,292 records were included in our study. The pooled incidences of VTE and PE were 6% and 3%, respectively. Subgroup analysis revealed that the tumour, node and metastasis (TNM) stage (HR= 5.43, 95% CI: 2.42, 12.22), metastasis (HR= 2.67, 95% CI: 1.35, 5.29) and chemotherapy (HR= 2.27, 95% CI: 1.11, 4.65) had major influence on VTE occurrence. Lung cancer complicated with VTE is unignorable, and its occurrence varies widely by tumour staging, tissue type and treatment. The results may aid in clinical decision-making about lung cancer in higher risk with VTE and weather receiving anticoagulant prophylaxis. The pooled incidences of VTE and PE were 6% and 3% in lung cancer. LUAD, NSCLC and tumour stage III-IV have significant relevant with VTE in lung cancer.
DOI: 10.6084/m9.figshare.25345309
title: Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials

description: Tenecteplase, a modified variant of alteplase with greater fibrin specificity and longer plasma half-life, may have better efficacy and safety than alteplase in patients with acute ischemic stroke (AIS). We aimed to compare the benefits and risks of tenecteplase versus alteplase in the treatment of AIS. Electronic databases were searched up to 10 February 2023 for randomized controlled trials evaluating the effect of tenecteplase versus alteplase in the treatment of AIS. The primary outcome was functional outcome at 90 days, and secondary outcomes including the symptomatic intracranial haemorrhage (SICH), and major neurological improvement. Subgroup analysis was performed based on the different dosage of tenecteplase. Ten studies with a total of 5123 patients were analysed in this meta-analysis. Overall, no significant difference between tenecteplase and alteplase was observed for functional outcome at 90 days (excellent: OR 1.08, 95%CI 0.93–1.26, <i>I</i><sup>2</sup> = 26%; good: OR 1.04, 95%CI 0.83–1.30, <i>I</i><sup>2</sup> = 56%; poor: OR 0.95, 95%CI 0.75–1.21, <i>I</i><sup>2</sup> = 31%), SICH (OR 1.12, 95%CI 0.79–1.59, <i>I</i><sup>2</sup> = 0%), and early major neurological improvement (OR 1.26, 95%CI 0.80–1.96, <i>I</i><sup>2</sup> = 65%). The subgroup analysis suggested that the 0.25 mg/kg dose of tenecteplase had potentially greater efficacy and lower symptomatic intracerebral haemorrhage risk compared with 0.25 mg/kg dose tenecteplase. Among AIS patients, there was no significant difference on clinical outcomes between tenecteplase and alteplase. Subgroup analysis demonstrated that 0.25 mg/kg doses of tenecteplase were more beneficial than 0.4 mg/kg doses of tenecteplase. Further studies are required to identify the optimal dosage of tenecteplase. Randomized controlled trials exploring comparative efficacy and safety of tenecteplase and alteplase have been yielding inconsistent results on various outcomes and merit the conduction of a meta-analysis to adequately answer these questions. Analysis of evidence from randomized studies suggests that tenecteplase is as safe as alteplase for the treatment of acute ischemic stroke and tenecteplase is potentially associated with more favourable outcomes. Tenecteplase at 0.25 mg/kg dose is more efficacious and at least as safe as alteplase for stroke thrombolysis.